Champions Oncology (CSBR) Non Operating Investment Income (2011 - 2015)
Champions Oncology (CSBR) recorded quarterly Non Operating Investment Income of -$420000.0 in Q2 2015, down 167.63% quarter-over-quarter from $621000.0 in Q1 2015, and down 277.22% on a YoY basis from $237000.0 in Q2 2014.
Champions Oncology (CSBR) Non Operating Investment Income (2011 - 2015) Analysis & Trends
Champions Oncology's Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$420000.0 for Q2 2015.
- In Q2 2015, Non Operating Investment Income fell 277.22% year-over-year to -$420000.0; the TTM figure through Jan 2016 stood at -$420000.0 (down 125.64% YoY), while the FY2015 annual figure was $981000.0, up 201.66% from the prior year.
- Non Operating Investment Income was -$420000.0 for Q2 2015 at Champions Oncology, down from $621000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $846000.0 in Q1 2014 to a low of -$1.5 million in Q3 2013.
- Historically, Non Operating Investment Income has averaged $18941.2 across 5 years, with a median of $66000.0 in 2012.
- The sharpest annual moves came in 2013 and 2014: Non Operating Investment Income plunged 1025.0% in 2013, then surged 547.17% in 2014.
- A 5-year view of Non Operating Investment Income shows it stood at $110000.0 in 2011, then plunged by 147.27% to -$52000.0 in 2012, then slumped by 1025.0% to -$585000.0 in 2013, then soared by 206.84% to $625000.0 in 2014, then slumped by 167.2% to -$420000.0 in 2015.
- The last three Non Operating Investment Income figures came in at -$420000.0 (Q2 2015), $621000.0 (Q1 2015), and $625000.0 (Q4 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Op. Investment Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2015 | -420,000.00 |
| Apr 30, 2015 | -420,000.00 |
| Jan 31, 2015 | 621,000.00 |
| Jan 31, 2015 | 621,000.00 |
| Oct 31, 2014 | 625,000.00 |
| Oct 31, 2014 | 625,000.00 |
| Jul 31, 2014 | 155,000.00 |
| Jul 31, 2014 | 155,000.00 |
| Apr 30, 2014 | 237,000.00 |
| Apr 30, 2014 | 237,000.00 |
| Jan 31, 2014 | 846,000.00 |
| Jan 31, 2014 | 846,000.00 |
| Oct 31, 2013 | -585,000.00 |
| Oct 31, 2013 | -585,000.00 |
| Jul 31, 2013 | -1.46 Mn |
| Jul 31, 2013 | -1.46 Mn |
| Apr 30, 2013 | -53,000.00 |
| Apr 30, 2013 | -53,000.00 |
| Jan 31, 2013 | -255,000.00 |
| Jan 31, 2013 | -255,000.00 |